Goals and conditions · Condition
Metabolic dysfunction-associated steatotic liver disease (MASLD)
ICD-10-CM K76.0
Fat in the liver together with at least one cardiometabolic risk factor, formerly called nonalcoholic fatty liver disease (NAFLD).
Biomarkers
Start with the primary markers, then add the companions that change how the primary result reads. Each link cites its source.
ALTPrimary marker
AASLD uses ALT with AST, age and platelets to calculate the FIB-4 fibrosis score.
Tests: Labcorp 19, Quest Diagnostics 19, with ranges on the biomarker page
AST P5PPrimary marker
AASLD uses AST with ALT, age and platelets to calculate the FIB-4 fibrosis score.
Tests: Labcorp 3, with ranges on the biomarker page
Glucose, Two-Hour PostprandialCompanion marker
Fasting glucose of 100 mg/dL or higher is one of the MASLD cardiometabolic criteria.
Tests: Labcorp 6, Quest Diagnostics 3, with ranges on the biomarker page
HDLCompanion marker
HDL-C of 40 mg/dL or lower in men or 50 mg/dL or lower in women is one of the MASLD cardiometabolic criteria.
Hemoglobin A1cCompanion marker
AASLD lists fasting glucose and HbA1c in the initial laboratory evaluation.
Tests: Labcorp 13, Quest Diagnostics 10, with ranges on the biomarker page
PlateletsCompanion marker
AASLD uses the platelet count in the FIB-4 fibrosis score.
Tests: Labcorp 45, Quest Diagnostics 11
TriglyceridesCompanion marker
Triglycerides of 150 mg/dL or higher are one of the MASLD cardiometabolic criteria.
Tests: Labcorp 34, Quest Diagnostics 16, with ranges on the biomarker page
Related
Sources
Clinical guideline
Consensus statement
We list which biomarkers a named source connects to this condition; we do not diagnose it. Interpret your own results with a licensed clinician, or track them in Aumnivida.